Track & Treat
Tracing COVID-19 vaccines worldwide
Researchers worldwide are working around the clock to find a vaccine against SARS-CoV-2, the virus causing the COVID-19 pandemic. Experts estimate that a fast-tracked vaccine development process could speed a successful candidate to market in approximately 12-18 months – if the process goes smoothly from conception to market availability.
To date, just one coronavirus vaccine has been approved. Sputnik V – formerly known as Gam-COVID-Vac and developed by the Gamaleya Research Institute in Moscow – was approved by the Ministry of Health of the Russian Federation on 11 August. Experts have raised considerable concern about the vaccine’s safety and efficacy given it has not yet entered Phase 3 clinical trials.
The pandemic has created unprecedented public/private partnerships.
The US government has chosen three vaccine candidates to fund for Phase 3 trials under Operation Warp Speed: Moderna’s mRNA-1273, The University of Oxford and AstraZeneca’s AZD1222, and Pfizer and BioNTech’s BNT162. Members of ACTIV have suggested developing safe controlled human infection models (CHIMs) for human trials could take 1-2 years.
Vaccineslab targeted to track lists COVID-19 vaccine candidates currently in Phase 1-3 trials, as well as major candidates in pre-clinical stages of development and research.
What We Do with Vaccines
Vaccine Developers Partner With Us
- We will jointly conduct clinical trials of your vaccine with Vacccineslab clinical development and commercialization capabilities in South East Asia
- Vaccineslab will commercialize the vaccine in South East Asia upon regulatory approval, with your firm retaining full rights to develop and commercialize the vaccine in the rest of the world
- Vaccineslab will secure funding and potential future investment and milestone payments, and share future gross profits from the sale of the vaccine in South East Asia
To learn more about Vaccineslab, COVID-19 vaccines funding and distribution, contact our regional specialist today.